Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00459238
Other study ID # CDR0000538178
Secondary ID R03CA119686P30CA
Status Completed
Phase N/A
First received April 9, 2007
Last updated May 16, 2017
Start date October 2006
Est. completion date December 2010

Study information

Verified date February 2017
Source Georgetown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Telephone-based cancer education and counseling may help participants learn about ways of preventing cancer and choose a lifestyle that will help them stay healthy as they grow older.

PURPOSE: This randomized clinical trial is studying telephone-based cancer education and telephone-based counseling to see how well they work compared with telephone-based cancer education alone in young participants.


Description:

OBJECTIVES:

Primary

- Compare the efficacy of telephone-based cancer education with vs without counseling in younger participants.

Secondary

- Determine the mechanisms by which education with counseling may impact cancer-relevant cognitive and behavioral outcomes.

- Identify teens who may be most and least likely to benefit from education with counseling.

OUTLINE: This is a pilot, controlled, randomized study. Participants are stratified according to age (13-14 years vs 15 years vs 16 years vs 17 years vs 18-21 years), gender, race (white vs black vs other), and health status (chronic disease vs no chronic disease). Participants are randomized to 1 of 2 education arms.

- Arm I: Participants undergo cancer education sessions via telephone over 45 minutes once a week for 8 weeks.

- Arm II: Participants under cancer education sessions as in arm I and counseling techniques during the same telephone sessions.

In both arms, participants receive an intervention kit by mail before the first telephone call. The intervention kit includes age-appropriate self-help materials.

PROJECTED ACCRUAL: A total of 300 participants will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date December 2010
Est. primary completion date December 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 21 Years
Eligibility DISEASE CHARACTERISTICS:

- No life-threatening illness (e.g., cancer)

- Chronic illnesses (e.g., asthma, diabetes) allowed with permission by physician

PATIENT CHARACTERISTICS:

- No serious restrictions on physical activity, diet, or nutrition, including any of the following:

- Untreated exercise-induced asthma

- Orthopedic or neurological problems

- Medical conditions affecting nutritional status, intestinal absorption, or response to nutritional intervention (e.g., inflammatory bowel disease)

- No serious mental illness or developmental disability that would preclude study compliance, including eating disorders

- Must adequately understand, speak, and read English

PRIOR CONCURRENT THERAPY:

- Not specified

Study Design


Related Conditions & MeSH terms

  • Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Other:
counseling intervention
subjects will receive telephone based counseling
educational intervention
subjects will received telephone based education

Locations

Country Name City State
United States Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington, D.C. District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Georgetown University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multiple risk factor index 6 months
Primary Knowledge 6 months
Primary Health history taking 3 months
Primary Nutrition 6 months
Primary Physical activity 6 months
Primary Tobacco use intentions and behavior 6 months
Primary Alcohol use intentions and behavior 6 months
Primary Screening intentions 6 months
Primary Self-efficacy 6 months
Primary Perceived benefits 6 months
Primary Perceived barriers 6 months
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Completed NCT00985868 - AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Completed NCT00253474 - PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Terminated NCT00176540 - Dextromethorphan in Treating Patients With Fatigue Caused by Cancer N/A
Completed NCT00070473 - Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Phase 1